Conjustar
Shanghai
About Conjustar
Conjustar, a protein-conjugated medicine developer that has rapidly built a robust R&D pipeline through a combination of introduction and independent research and development. it delivers more effective and safer new cancer therapy options to the majority of cancer patients.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $41.5M
- Funding stage: Seed
- Last round: Seed (Jan 2025)
- Website: conjustar.com
- Phone: 021-33670826
Industries & Categories
Health Care, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/conjustar-28281 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.